



2018 ANNUAL REPORT

Leading the Way to
2030



Leading the Way to 2030

FOR NEARLY THREE DECADES, the Hepatitis B Foundation and our research arm, the Baruch S. Blumberg Institute, have been leading the charge to bring hepatitis B outreach, research and advocacy to the forefront. We have adopted a bold strategy to give a louder voice to this silent epidemic—bringing it into the spotlight to elevate awareness, increase vaccination, screening and linkage to care, accelerate research, and ultimately cure this deadly disease.

Our five-year strategic plan, approved in 2018, is rooted in an aggressive vision:

BY 2030, NO ONE DIES FROM HEPATITIS B.

WE ARE CONFIDENT THAT A CURE FOR HEPATITIS B IS WITHIN OUR REACH, and we are recruiting the best scientists in the field to encourage collaboration, share their progress, and bring a cure to market. We recognize, however, that a cure alone is not enough for our vision. Our plan also includes continuing and expanding our existing programs to emphasize prevention, and provide critical assistance for those managing the disease. Through our Hep B United program, we have set the standard for building coalitions within at-risk communities to provide free awareness, testing, and linkage to care. We have implemented a ground-breaking global initiative in Haimen City, China, that will act as a model as we expand into other highly-affected regions of the world. And we continue to provide information and guidance directly to thousands of people who contact us for help each year. **Your commitment to our mission** has made all these programs possible, and your continued support will bring us even closer to our vision of a world where hepatitis B is no longer deadly.


Fifty years after its discovery, hepatitis B is still the most common liver disease in the world. It thrives in silence, but our voices together can make hepatitis B history. We have a clear plan in place to lead hepatitis B into the forefront of scientific advances and public health planning, and eliminate deaths from this virus within our lifetimes. **Your continued support** has made these advances possible.



The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation's leading nonprofit disease advocacy and research organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991 and established the Blumberg Institute in 2003 to fulfill its research mission.

SCIENTIFIC RESEARCH

Leading the way to A CURE



THROUGH OUR RESEARCH ARM, the Baruch S. Blumberg Institute, we are relentlessly researching promising new innovative treatments for liver cancer and a cure for hepatitis B. Nearly 50 scientists work at our Blumberg Institute—**one of the largest nonprofit groups of researchers investigating hepatitis B, liver cancer, and other liver diseases in the world.** Our work extends beyond our own laboratories, to the larger hepatitis B research community. In 2018, our **Roadmap to a Cure** was

published in *Hepatology*, providing a consensus statement from leading researchers to identify the most promising areas of focus for hepatitis B and liver cancer science, and approaches considered necessary for a cure.

WE EXPECT MORE OF OUR DISCOVERIES, and discoveries that we inspire, to reach human trials soon. Our successes from the past year are highlighted in this report.

ADVANCING HEPATITIS B AND LIVER CANCER RESEARCH

Reaching clinical trials

4 of our promising findings moved into clinical trials in 2018, including two for hepatitis B treatment, one for cancer treatment and one for cancer detection

Reaching the scientific community

Our Scientists published 40 peer-reviewed publications in leading research journals

Keeping a focus on drug discovery and the basic science of disease, we have:

- Identified compounds with novel activity against HBsAg
- Identified new biomarker to detect liver cirrhosis and liver cancers
- Identified a novel compound, KPD10, through our cell-based high-throughput compound screening, which selectively kills HCC cells expressing HBV surface antigen

- Found method of selective killing of hepatocellular carcinoma cells by exploiting HBV surface antigen expressed on HCC cells
- For use as a new, non-invasive marker of HCC, identified HBV sequences integrated adjacent to cell oncogenes from the urine of people with HCC
- Identified cellular proteins that HBV needs to produce cccDNA and to repress cccDNA expression

- Discovered HBV's unusual process of producing its "mRNA"
- Found STING agonist as therapeutics for cancers and chronic viral infectious diseases
- Identified and characterized antiviral drug candidate against yellow fever virus, with a new mechanism of action

See hepb.org/research for more information on our research accomplishments.

BRINGING LEADERS TOGETHER



We provided expert presentations at over 25 national and international conferences

More than 500 hepatitis B and liver cancer scientists attended the 2018 International HBV Meeting in Taormina, Italy, coordinated by HBF

We hosted 30 seminars by scientific leaders at Baruch S. Blumberg Institute

TRAINING THE RESEARCHERS OF TOMORROW



7 Post doctoral Fellows

from universities worldwide

18 Graduate Students

from Drexel University, Geisinger Commonwealth School of Medicine and The University of Pennsylvania trained at Blumberg Institute

6 Medical Students

from Xavier Medical School conducted research rotations at Blumberg

3 Junior Research Fellows

joined our labs to prepare themselves for careers in science and business

7 Undergraduate College Students

from Drexel, Cornell, Temple, Penn State conducted research in our labs

25 High School Students

trained through our new educational programs this year as part of our commitment to tomorrow's scientists. An exciting new collaboration with Central Bucks School District brought 15 advanced placement chemistry students to the Blumberg Institute every day to conduct real-world research in our labs. Another 10 high school students participated in our celebrated summer program.

OUTREACH & PATIENT EDUCATION


Leading the way to BETTER HEALTH

HEPATITIS B CAN BE an overwhelming and confusing diagnosis. Our trained staff answer questions about test results, transmission, vaccinations, and care, and help patients to understand what their diagnosis means for their health and their future. We guide people with hepatitis B as they face their diagnosis, and provide guidance for telling loved ones, finding care, and starting a family.

This year, we educated patients, family members, employers and health officials through:

In 2018, we started collecting caller data from phone consults.

Our callers asked about:



#justB NATIONAL STORYTELLING CAMPAIGN SHINES A SPOTLIGHT ON HEPATITIS B

There is no better way to raise public understanding about the true impact of hepatitis B than through personal stories. In 2017, the Hepatitis B Foundation unveiled its #justB national storytelling campaign with real people sharing their stories about hepatitis B. This national storybank is designed to put a human face on hepatitis B in order to increase public awareness, decrease stigma and discrimination, and to promote testing and treatment, which will ultimately save lives.

Forty storytellers share their experiences with hepatitis B and liver cancer both online, and at in-person educational events throughout the U.S. Over 2.2 million people have viewed our stories, improving awareness around the world.

You can watch all our #justB stories at www.hepb.org/justb.



CONNECTING PATIENTS WITH OUR PROGRAMS

In addition to hepatitis B outreach, we also offer programs to provide support and information for conditions that impact people with hepatitis B:

Hepatitis Delta Connect aims to increase awareness and education about this deadliest form of viral hepatitis, which only infects those with hepatitis B. Information is available in 3 languages, and we have connected with 500 individuals for consults, and reached 3,000 people through our educational webinars.

Visit www.hepDconnect.org.

Liver Cancer Connect works to educate those at risk for liver cancer and provides support through its email helpline and social media channels for patients and families. Visit www.livercancerconnect.org.

PUBLIC HEALTH

Leading the way to ELIMINATING HEPATITIS B

TO REACH OUR GOAL of reducing deaths from hepatitis B, the Hepatitis B Foundation issued a formal recommendation this year that **all Americans be tested** for hepatitis B. To bring the disease to the forefront, we must be aggressive in our efforts to test, vaccinate, treat, and prevent the spread of hepatitis B. But we can't stop there. We will continue to build new coalitions, and support existing efforts to **ensure that every infected person knows their status and has access to care that can save their life.**

HEP B UNITED

Hep B United, a national coalition established by HBF in partnership with the Association of Asian Pacific Community Health Organizations, has demonstrated great success in bringing community leaders, providers, medical and public health students, and state and local health departments together with at-risk communities. Hep B United added 4 new partners this year bringing our reach to **30 cities in 21 states.**

Hep B United brought over 80 of our coalition partners together for its **6th Annual National Summit** to advance our movement to address and eliminate hepatitis B. The Hepatitis B Foundation also facilitates our local coalition, Hep B United Philadelphia (HBUP), which serves a vital role as a mentor for newly-formed coalitions in other cities, and as a testing ground for new programs.

In 2018, Hep B United Philadelphia educated **over 2,000 people**, screened 150, and linked 90% of infected individuals to care. We also hosted professional trainings for over 150 clinicians and public health partners.

Increasing awareness, screening, vaccination and linkage to care



Hep B United Summit brought over 80 of our hepatitis B coalition partners together for HBU's 6th Annual Summit to advance our movement to address and eliminate hepatitis B.



COALITION AGAINST HEPATITIS IN PEOPLE OF AFRICAN ORIGIN



HBF leads the national Coalition Against Hepatitis in People of African Origin (CHIPO), a community coalition of organizations to address the high rates of hepatitis B infection among African communities in the U.S. This year, our work included a collaboration with the Centers for Disease Control and Prevention (CDC) to create a broad scale educational initiative to promote hepatitis B awareness and testing for African immigrants across the United States. This exciting project is the first of its kind to provide targeted educational materials to often-overlooked African immigrant communities.

INTERNATIONAL REACH

Since 2011, the Hepatitis B Foundation has sponsored an ambitious public health campaign in Haimen City, **China** to reach all 1 million residents with information about hepatitis B. Building on our success in China, we have partnered with organizations to help them bring hepatitis B awareness, testing and care in Ho-Chi Minh, **Vietnam** and Accra, **Ghana**.






ADVOCACY

Leading the way by TAKING ACTION

THROUGH OUR EFFORTS, the hepatitis B voice has grown steadily louder in Washington, DC. As the recognized authority on the fight against hepatitis B, The Hepatitis B Foundation has led the charge to bring government attention and funding to the epidemic of viral hepatitis.

We have also worked to fight persistent discrimination that people with hepatitis B face as they apply to work, go to school, enlist in the military, and seek healthcare.



HEP B CURE CAMPAIGN

Hepatitis B has long been underfunded in contrast to government spending on similar epidemics. The Hepatitis B Foundation has focused our efforts on a major advocacy campaign, the Hep B Cure Campaign, aimed to **double federal spending on hepatitis B**. Our Cure Campaign has already seen success with publication of our *Roadmap for a Cure*, which identifies areas of promising research and funding. We are working to continue our efforts to increase funding for research by \$39 million a year for the next six years, and are advocating for better coordination of research through the National Institutes of Health.

HEP B UNITED ADVOCACY DAY BRING THE MESSAGE TO WASHINGTON

During the **Hep B United Advocacy Day**, nearly 70 advocates met with more than 60 Congressional offices to discuss increasing federal resources to address and eliminate hepatitis B and liver cancer. We also now reach over 430 people through our online grassroots advocacy network, at hepbunited.org.

FIGHTING DISCRIMINATION IN THE U.S.

The Hepatitis B Foundation is working tirelessly to end the stigma and ensure that people with hepatitis B are afforded the same opportunities as everyone else. Our advocacy successfully made hepatitis B a protected condition under the Americans with Disabilities Act (ADA) in the United States, and we continue to fight to ensure that people receive those protections. In addition to ensuring that medical schools and employers comply with ADA protections, we are also fighting for fair access to medicines. [Learn more about our work at hep.org/rights](http://hepb.org/rights).



OUR VISION

Leading the way to a
WORLD WHERE NO ONE DIES OF HEPATITIS B

THE HEPATITIS B FOUNDATION IS committed to a future without hepatitis B, and we have a plan to get there. In 2018, we adopted an ambitious five-year plan based around the vision that by 2030, no one dies of hepatitis B. Our *Roadmap to Cure* provides a blueprint for the research necessary to bring better treatments and a cure, and our public health priorities support the education, awareness and infrastructure needed to stop the spread of the virus.

ACHIEVING OUR VISION WILL REQUIRE A GLOBAL FOCUS TO EXPAND OUR RESOURCES AND CAPABILITIES ACROSS THE WORLD IN ORDER TO »





Create a Patient Voice

Our presence in communities of high prevalence must increase. Education, awareness, and advocacy on behalf of individuals fighting discrimination and stigma is underway, but we know there are many more cases of people suffering from workplace, military, and educational access discrimination. Working with our coalition of partners across the country, we can help them scale up efforts in over 20 states.



Improve International Capacity

Internationally, resources are scattered and uncoordinated. But the Hepatitis B Foundation is poised, as the global leader in this space, to take on the challenge and build an international coalition similar to the United States Hep B United model, resulting in “Hep B United Global” or “HBUG”. This will lay the groundwork for projects in 5 different countries around the globe to save millions of lives.



Foster discovery of a cure for hepatitis B

We need to give the scientists of the Baruch S. Blumberg Institute the tools to conduct cutting edge research. Vision, commitment and patience is required to accelerate the pace toward a “functional” cure, which we believe exists somewhere within the new wave of HBV therapeutics.



THANK YOU TO OUR DONORS



The Hepatitis B Foundation's valuable research and programs are made possible by the commitment of our donors. We are grateful to every individual and organization that has generously supported our mission to find a cure and improve the quality of life for those affected by hepatitis B.

Our Donor Honor Roll

JANUARY - DECEMBER 2018

VISIONARY CIRCLE (\$10,000 AND ABOVE)

Anonymous
 Arbutus Biopharma
 Timothy & Joan M. Block
 Carol and Edmund Blake Foundation
 Dynavax
 Eiger Biopharmaceuticals, Inc.
 Fred Beans Family of Dealerships
 Gilead Sciences, Inc.
 Kahn Charitable Foundation,
 Shannon Wu & Joseph Kahn
 Prevent Cancer Foundation
 Quest Diagnostics
 RFS Family Foundation,
 Raymond Schinazi
 Roche-Genentech
 Spring Bank Pharma
 Univest Corporation of PA
 Catharine & Rob Williams

GLOBAL CIRCLE (\$5,000 TO \$9,999)

Alnylam US, Inc.
 Arrowhead Pharmaceuticals Inc.
 Assembly Biosciences, Inc.
 Bristol-Myers Squibb
 Alan & Patty Brownstein
 CTC Foundation
 Linda London
 Merck & Co.
 Penn Community Bank
 Software Inc.
 Priscilla Tennant
 Paula Wong & W. Robert Magee, Jr.

FOUNDER'S CIRCLE (\$2,500 TO \$4,999)

Nathaniel Brown
 Bonnie Chang & Robert Hsu
 EisnerAmper LLP
 Anthony & Jane Ford-Hutchinson
 Herman Goldman Foundation
 High Swartz LLP
 KMT Hepatech Inc.
 Faye & Mayer Krupp Family
 Charitable Foundation
 Lion TCR
 Bruce & Cynthia Maryanoff
 Norwood Company
 Joel Rosen
 Worldwide Life Sciences

PRESIDENT'S CLUB (\$1,000 TO \$2,499)

Abbott Laboratories
 ADMA Biologics, Inc.
 Jon Biedermann
 Blank Rome LLP
 Stanley & Gerri Broadbent
 Carol Brosgart
 Bob & Joyce Byers
 Richard & Flo Celender
 Gang Chen
 Moon Chen
 Chari & Paul Cohen
 Steve & Janet Cohen
 Thomas Shenk & Lillian Chiang
 Molli & Joe Conti
 David Family Charitable Foundation
 Craig & Janet Esterly
 Fisher Scientific
 Fulton Bank Premier Division

Geisinger Commonwealth
 School of Medicine
 Gilmore & Associates Inc.
 Glycotest
 Adam Grossman
 David & Cynthia Gruber
 Anne Heacock
 Ram Kapur
 Kevin Kruse
 Lafayette Ambassador Bank
 Patrick Lam
 Arthur & Nancy Laskin
 James Laskin
 Limbach Co. LLC
 Mary Anne McDonald & Joseph Benning
 Richard Moyer
 Network for Good
 Anna O'Connell
 Timothy Ocain
 OrthogenRx, Inc.

Penn Color, Inc.
 Yusheng Qu
 Richman Chemical Inc.
 Spark Nonprofit Consulting LLC
 Stark & Stark
 Tulchin Family Foundation
 Nagachaitanya Vellanki
 Michael Wehner
 Wojdak Government Relations
 Worth & Company, Inc.
 Wayne Yetter
 Tianlun & Amy Zhou

PATRONS (\$500 TO \$999)

Matthew & Wendy Adlai-gail
Anonymous
Clement Au
Eileen Beck
Bee Bergvall & Co.
Terri Chen
Conifer Point Pharmaceuticals
CP Commercial Printing
William Delaney
Demusz Brothers, Inc.
Donation Line, LLC
Yanming Du
Greene Street Pharmaceuticals
Maureen Kamischke
Louis & Jeannie Kassa
Kathleen Kerrigan
Anna Lee
Lewis and Rosebud Roberts Family Fund
Madison Associates, LLC
Michele Nasti
Debora Nelson
Rasna Therapeutics
Lewis Roberts
Samuel P. Mandell Foundation
Daniel and Lena Solaiman
Michael & Charleen Sofia
Leaf Sternberg
Lishan Su
Ying-Hsiu Su & Wei Song
Tiziana Life Sciences
Jeane Vidoni
A. Rhodes Wilson
Paul & Jan Witte

FELLOWS (\$250 TO \$499)

Leo Adalbert
Ark Pharm
Blooming Minds Design, LLC
Gregory and Susan Braithwaite
Anthony Cha
Daniel Chan
Jinhong Chang
Joly Chang
Feng Chen
Del Val Power and Light, Inc.
Sejong Ding
John Ellis
Karl Emerson
Brian C Eves, Esq.
Lalo Flores
Daniel & Jamie Fox
Fox Chase Chemical Diversity Center
Alan Freedman
Anne Frey
Frontier Scientific
Roger & Nancy Gallic
Graphic Edge, Inc.
Richard Grillo
Ronyi Gu
Ju-Tao Guo
Hie-Won Hann
Franklin & Carol Hart
Virginia Heatwole
Jean Holmes & Lisa Mathason
Eva Honsa-Hogg
ImmunoRestoration, Inc.
InterLink Biotechnologies

IteraMed Consulting LLC
JBS Science, Inc.
Joanne Jensen
Margaret Keenan
Robert Kelley
Peter Lamberts
Jennifer Maher
Brian McMahon
Loujan Mourad
Moyer Indoor Outdoor
PNC Wealth Management
Kenneth & Maria Rothstein
Guiseppe Sarrica
Caroline Satchell
Christoph & Mirjam Seeger
Susan Stellini
Tesco Inc.
Walter Tsou
Dennis Wen
Woodmansee & Co.
George and Cathleen Woods
Anchi Wu
Mary Yee
Cheng Zeng

SUPPORTERS (\$100 TO \$249)

Ishola Adeyemo
Ovidiu Aldea
Laurie & James Beckert
Susan Bellaire & John Massey
Sandra Bendt
Joanne Blasenheim
Jennifer Boardman
Bill & Mary Kell Cayley
Everett & Diana Chambers
Garrett Chang
Cong Cheng
David & Kathleen Christenson
Margaret Copeland
Andy Cuconati
Zebene Deresse
Mary Cushing Doherty
William Donaldson
Mike Dugery
Exude, Inc.
Theodore Feldstein
Kurt & Janet Ferguson
Edward Fischer
KT Foundation
Brian Free
Lawrence Friedman & Mary Jo Cappuccilli
Curt & Rosanne Friehs
Edan Gal
Michelle Gerber
Joseph Gonnella
William Green
Hunt Hawkins & Elaine Smith
David Hines
Peter Hoekstra
Max Holt
Kenny Hom
Yuko Hwang
Julie Jacob
Jeffrey Jacobson
Amy Jessop
Donald & Kimberly Jungkind
Karen Lassman-Eul

Peter Leone
Edward Lin
Michael Line
Amy Liu
Dapeng Liu
Jessica Lorenz
Kenneth Lu
Emily Mao McCarty
Jennifer Miller
James & Barbara Mongold
Catherine Morris & Richard Bader
Markus Musa
Meredyth Nash
Deigo Mora Navarro
Richard & Teresa O'Flynn
John Oldani
Anthony Oppenheim & Cathy Block
Val Orekhov
Linda Park
Steve Pelland
Janet Perper
Rupali Praveen
Paul Raetsch
James & Kathleen Ryan
Jasmin Sabado
Ronald & Joyce Sanderson
Y. Clement Shek
Toby Sherwood
Jim & Kathleen Shryock
Thomas & Harriet Stenzel
SteroTherapeutics, LLC
Linhui Sui
David Sul
Susan Sun
James Talamonti
Judy Tam
Gary Triozzi
Philip & Philippa Wharton
Roy Williams
Shari & Steve Winkler
Stephen Wong
Onanong Wongwichai
Kechang Wu & Yuling Lo
Yalin Xiong
Shihyun You
Marissa Yu
Thomas Zipp

FRIENDS (UP TO \$99)

Joann Albert & Daniel Green
V. Alexiades
Kyle Anderson
Priyanka Banerjee
Patricia Benham
Janet Bergstrom
Kamlesh Bhagnani
Steven Bingham & Jack Leonard
Steve Black
Geraldine Block
Ron & Debbie Blough
Stephen Borowski
Elaine Brennan
Robert Britt
Nelson Campbell
Paolo Cecchetti
Ka-Ming Chan

Manju Chatani
 Li-Heng Chen
 Rachel Cheng
 Ksheerasagar Chintalapalli
 Stephen Chow
 William & Rita Clark
 Robert Cohoon
 Joan Copp
 Raymond D'Auria
 Daniel DiMaria
 Sheryl Dominguez
 Ronald Drakeford
 John & Sandy Draus
 Donna Dunham
 James Dzikowski
 ECHO of Northrop Grumman
 EFB, Inc. Franchise of Uno
 John Estok
 Glenn Galang
 Richard Garza
 David Gaskin
 Gabriel Gavrilesco
 Sudhanva Gnaneshwar
 Rylan Goudreau
 Renee Haliburton
 Deborah L. Hennel
 Xiaoling Hong
 Nhi Hua
 Paing Huang
 Shabbir Husain
 Jane Johnston
 Suzanne Kahn
 Christie Kan
 Nina & Paul Katz
 Jenny Kimbel
 Mariemel Latorre
 Abraham Leibson & Sharon Victor
 Michelle Levesque
 King & Ying Liang
 Neil Liu
 Hoang Ma
 Maria Macwilliams
 Paul Man

Judith Marchand
 Kerry Marshall
 James Massie & Janice Scott
 Jim McGowan
 Lynne Mercedes
 Tulin Morcol
 Xiaohong hu Mueller
 Pallavi Nimkar
 Jason Nunez
 Jeanne Oesch
 Emily Oppenheim
 Meg & Michael Ovitt
 John Perez
 Edward Peritz
 Ted Popper
 Polly Ranson
 Anna Ridout
 William Ryle
 Nick Sasomsub
 M Rafi Shaik
 Myong Shin
 Musa Shodunke
 Ping Shyr
 Priscilla Smith
 Denise Stern
 Ray Tai
 Lance Than
 Robert Thrane
 Patricia Trainor
 Albert Tsai
 Harry C. Tse
 Hin Tse
 Heng FU Tseng
 Charles Wagner
 Carrie Welch & Sherman Labarge
 Vanessa Wenzell
 Helen Wise
 Adelynn Woodard
 Jay Wrobel
 Laura Young
 Xinxian Zhang
 Leo Zheng
 Mei Zheng



HEPATITIS B FOUNDATION LEGACY SOCIETY

Recognizing donors who have included HBF in their wills or made a planned gift

Timothy and Joan Block
 Craig and Janet Esterly
 Jean Miller
 C. Theodore Tucker
 Catharine and Rob Williams
 Paul and Janine Witte



MATCHING GIFT PROGRAMS

Amazon Smile Foundation
 America's Charities
 Amgen Foundation Matching Gift Program
 AT&T United Way Employee Giving Campaign
 Bank of America Employee Giving Campaign
 Benevity Community Impact Fund
 Give with Liberty Campaign
 IBM Employee Services Center
 JP Morgan Chase Employee Giving
 Merck Partnership for Giving
 Nvidia Employee Giving Program
 Pledgeling Foundation
 United Way California Capital Region
 United Way of the Bay Area
 YourCause, LLC

Thank you

**TO OUR MANY IN-KIND DONORS WHO
 ARE TOO NUMEROUS TO MENTION.**





.....

We apologize in advance for any errors or omissions in our Donor List despite our best efforts to be as accurate as possible. Please email editor@hepb.org or call (215) 489-4900 so that we can print corrections in our next newsletter. Thank you for understanding.

Year In Review + Financial Information*

COMBINED HEPATITIS B FOUNDATION
& BARUCH S. BLUMBERG INSTITUTE**

FOR THE FISCAL YEAR ENDED JUNE 30, 2018



* The financial information presented above does not include the activity from Hepatitis B Foundation's ownership of the net assets of the Pennsylvania Biotechnology Center. At June 30, 2018, this interest was valued at, based on the equity method of accounting, approximately \$4,959,000 per the audited Statement of Financial Position of the Hepatitis B Foundation.

** The financial information presented above excludes unrealized investment related activities.

*** Excludes in-kind donations

**** **Baruch S. Blumberg Institute** is the research institute established by the Hepatitis B Foundation in 2004

The financial information in this report was prepared by management and presented in condensed form from the financial statements of the Hepatitis B Foundation and the Baruch S. Blumberg Institute audited by EisnerAmper, LLP for the year ended June 30, 2018. A copy of each financial statement is available upon request.

The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation's leading nonprofit research and disease advocacy organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991, and established the Baruch S. Blumberg Institute in 2003 to fulfill its research mission.

HBF BOARD OF DIRECTORS

Chairman

Joel Rosen, Esq.

President

Timothy M. Block, PhD

Vice President

Catharine Williams, MGA

Treasurer

Joseph Hediger

Secretary

Wayne Yetter

Stanley Broadbent

Carol Brosgart, MD

Nathaniel Brown, MD

Alan Brownstein, MPH

Loren Danzis, Esq.

Craig Esterly

Anthony Ford-Hutchinson, PhD

David Gruber, CPA

Raman Kapur, MBA

Thomas Shenk, PhD

Walter Tsou, MD

Su Wang, MD, MPH

Medical and Scientific Advisors

Harvey Alter, MD

Timothy M. Block, PhD

Carol Brosgart, MD

Nathaniel Brown, MD

Francis Chisari, MD

Raymond Dwek, D. Phil, FRS

Anthony Ford-Hutchinson, PhD

Lawrence Friedman, MD

Don Ganem, MD

Robert Gish, MD

Hie-Won L. Hann, MD

Stephen Locarnini, MD, PhD

Anna Lok, MD

William Mason, PhD

Brian McMahon, MD

Edith Mitchell, MD

Robert P. Perillo, MD, FAASLD

Lewis Roberts, MB, ChB, PhD

Kenneth Rothstein, MD

Raymond Schinazi, PhD

Thomas Shenk, PhD

John Tavis, PhD

Board Members Emeritus

Joan M. Block, RN, BSN

Janine Witte

In Memoriam:

Baruch S. Blumberg, MD, DPhil

Nobel Laureate

W. Thomas London, MD

Bud Tennant, DVM

Medical Director

Robert Gish, MD

Special Advisors

Bob Bowman, PhD

Gang Chen, MD, PhD

Eddie Cheung, MD

Nadine Shiroma

STAFF

President

Timothy M. Block, PhD

**Executive Vice President/
Chief Operating Officer**

Louis P. Kassa, III, MPA

Senior Vice President

Chari Cohen, DrPH, MPH

Vice President, Research

Ju-Tao Guo, MD

Vice President,

Institutional Advancement

Jean Holmes, MBA

Outreach and Public Health

Catherine Freeland, MPH

Michaela Jackson, MS

Maureen Kamischke

Kate Moraras, MPH

Sierra Pellechio, CHES

Rhea Racho, MPAff

Institutional Advancement

Jenny Kimbel

Susanna McGrogan

Megan Pierce

Finance and Operations

Deborah Blough

Chris Cheshire

Nicole Grasso

Mark Hansen

Konrad Kroszner

Judith Marchand

Patti McAloon, MBA

Dianna Miller

Loretta Molle

Ray Savage

**BARUCH S. BLUMBERG
INSTITUTE BOARD OF
DIRECTORS & OFFICERS**

Chairman

Wayne Yetter

President

Timothy M. Block, PhD

Treasurer

Joseph Hediger

Secretary

Louis P. Kassa, MPA (non-voting)

Loren Danzis, Esq.

Joel Rosen, Esq.

Thomas Shenk, PhD

Michael Sofia, PhD (non-voting)

**HEPATITIS B FOUNDATION
AND BARUCH S. BLUMBERG
INSTITUTE FACULTY**

Timothy M. Block, PhD

Jinhong Chang, MD, PhD

Jason Clement, PhD

Chari Cohen, DrPh, MPH

Yanming Du, PhD

Catherine Freeland, MPH

Ju-Tao Guo, MD

Xuanmao Jiao, PhD

John Kulp, PhD

Patrick Lam, PhD

Zhiping Li, PhD

Bruce Maryanoff, PhD

Sung Park, PhD

Richard Pestell, MBA, MD, PhD

Aejaz Sayeed, PhD

Kunwar Shailubhai, PhD, MBA

Ying-Hsiu Su, PhD

Roshan Thapa, MD

Matthew Todd, PhD

Tianlun Zhou, MD, PhD, MPH

Teaching & Lab Faculty

Sahithi Pamarthy, PhD

Darl Swartz, PhD

Wei Xie, PhD

Fanny Zhang, PhD

On-site Adjunct Faculty

Dennis Gross, MBA, PhD

Nikhil Heble, JD, PharmD

David Horn, MD

William Kinney, PhD

Cynthia Maryanoff, PhD

Raj Patil, PhD

Patrick Romano, PhD

Michael Sofia, PhD

Off-site Adjunct Faculty

Gang Chen, MD, PhD

Andrea Cuconati, PhD

Doan Dao, MD, PhD

Richard Davidson, PhD

Alison Evans, ScD

Nicholas Meanwell, PhD

Chris Moore, PhD



Join Our Global Conversation



/hepbfoundation



@hepbfoundation



@hepbfoundation



/hepbfoundation



hepb.org/blog



@hepbfoundation

3805 Old Easton Road, Doylestown, PA 18902

Phone: (215) 489-4900 Fax: (215) 489-4920 Email: info@hepb.org

Visit www.hepb.org and www.blumberginstitute.org

